AstraZeneca PLC (AZNCF)
OTCMKTS · Delayed Price · Currency is USD
190.99
+2.49 (1.32%)
At close: Jan 9, 2026
AstraZeneca Revenue
AstraZeneca had revenue of $15.19B in the quarter ending September 30, 2025, with 11.99% growth. This brings the company's revenue in the last twelve months to $58.13B, up 13.52% year-over-year. In the year 2024, AstraZeneca had annual revenue of $54.07B with 18.03% growth.
Revenue (ttm)
58.13B
Revenue Growth
+13.52%
P/S Ratio
5.08
Revenue / Employee
616.41K
Employees
94,300
Market Cap
295.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 787.00M | 2.40% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Northwest Biotherapeutics | 937.00K |
AstraZeneca News
- 6 hours ago - AstraZeneca: Oncology Dominance Justifies New All-Time Highs - Seeking Alpha
- 9 hours ago - Walmart to replace AstraZeneca on Nasdaq 100 effective Jan. 20 - Seeking Alpha
- 10 hours ago - Walmart (WMT) Joins Nasdaq-100 Index, Replacing AstraZeneca (AZN) - GuruFocus
- 17 hours ago - Walmart To Join Nasdaq-100 Index As AstraZeneca Exits In January 2026 Reshuffle - Nasdaq
- 20 hours ago - Walmart to Join Nasdaq-100, Replacing AstraZeneca - GuruFocus
- 1 day ago - Healthy Returns: What to expect from pharma at the JPM conference - CNBC
- 1 day ago - Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know - Nasdaq
- 2 days ago - AstraZeneca names Rick Suarez head of US biopharmaceuticals unit - Reuters